Pseudomonas aeruginosa is one of the most clinically threatening and drug-resistant pathogens, ranking second among the 12 superbugs most urgently in need of antimicrobials (World Health Organization, 2017). In 2022, more than 420,818 cases of P. aeruginosa infections were detected in Chinese medical institutions, with a 16.6% drug resistance rate to carbapenems (CRPA).

The phage library of P. aeruginosa at CreatiPhage is characterized by high quality, comprehensive information, and broad intra-specie coverage. Therefore, CPD-PA01 is a natural phage cocktail that broadly targets clinically prevalent strains of drug-resistant P. aeruginosa. It is in liquid form and indicated for wound infections. In preclinical studies, it demonstrated broad-spectrum bactericidal activity against P. aeruginosa isolates associated with wound and pulmonary infections, with a favorable animal safety profile. An investigator-initiated phase 1/2 randomized controlled clinical trial conducted in collaboration with partner institutions has now completed patient enrollment.

Acinetobacter baumannii accounts for over 400,000 related deaths annually worldwide, ranking first among 12 superbugs (World Health Organization, 2017). In China, 220,000 cases of Acinetobacter baumannii infections were detected in healthcare facilities in 2020, 53.7% of which were resistant to carbapenem antibiotics (CRAB), with no new antibiotics available. 

CreatiPhage's A. baumannii phage library is of high quality, with comprehensive information and wide strain coverage. The CPD-AB01, a natural phage cocktail covering drug-resistant strains, is currently undergoing preclinical studies. The initial pipeline is indicated for lung infections, with the phage formulation being a liquid administered via inhalation.

Klebsiella pneumoniae is the most clinically threatening and most drug-resistant member of the Enterobacteriaceae, causing more than 600,000 related deaths globally each year and ranking third among the 12 major superbugs released by the World Health Organization in 2017. In 2022, medical institutions in China detected a total of 748,000 cases of K. pneumoniae infection, among which the resistance rate to third-generation cephalosporins (CRE) was as high as 27.7%, and the resistance rate to carbapenems (CRKP) reached 10%.

CreatiPhage's Klebsiella pneumoniae phage library is of high quality, comprehensively annotated, and broad in strain coverage. CPD-KP01 is a natural phage cocktail with broad-spectrum coverage of clinically prevalent drug-resistant K. pneumoniae strains. Its lead pipeline indication is urinary tract infection; the phage formulation is a liquid, administered by intravesical instillation.

Pseudomonas aeruginosa causes more than 300,000 related deaths globally each year and ranks second among the 12 major superbugs released by the World Health Organization in 2017. In 2020, medical institutions in China detected a total of 281,000 cases of P. aeruginosa infection, of which 18.3% were superbugs resistant to carbapenems (CRPA). Because of factors such as its propensity to form biofilms, the population suffering from chronic infections caused by P. aeruginosa, including pulmonary and urinary tract infections, is enormous; antibiotic treatment outcomes are poor, and new drug development is urgently needed.

Scientists in CreatiPhage have long conducted phage–P. aeruginosa research. They possess a high-quality, well-annotated, broad-coverage phage library against P. aeruginosa and genetic manipulation technologies. Their ongoing research project is supported by the Young Scientists Project of the National Key R&D Program in Synthetic Biology. CPD-SynPA01 is a gene-edited phage cocktail with ultra-broad-spectrum coverage against drug-resistant P. aeruginosa and is currently at the laboratory research and development stage.

Acinetobacter baumannii causes more than 400,000 related deaths globally each year and ranks first among the 12 major superbugs released by the World Health Organization in 2017. In 2020, medical institutions in China detected a total of 220,000 cases of A. baumannii infection, of which 53.7% were superbugs resistant to carbapenems (CRAB), with no new antibiotics available for treatment.

Scientists in CreatiPhage have long been engaged in phage–A. baumannii research and possess a high-quality, well-annotated, broad-coverage phage library against A. baumannii as well as genetic manipulation technologies. CPD-SynAB01 is a gene-edited phage cocktail with ultra-broad-spectrum coverage against drug-resistant A. baumannii and is currently at the laboratory research and development stage.

The first step in personalized phage therapy and customize services is selecting lytic phages from the target bacteria's corresponding cPhageBank which has a huge future diagnostic market. CreatiPhage has developed the second-generation plaque/killing-curve phage screening technologies (TestiPhi™ Solid/Liquid Screening) and planned the third-generation virtual cPhageBank screening technology (ComputiPhi™ Screening). The second-generation plaque screening method, paired with CreatiPhage's co-developed intelligent identification scoring report system, allows for high-throughput screening of 96 phages per agarplate, using image-based intelligent recognition to lock onto lytic phages for conventional growth-speed clinical bacteria within 8 hours. The liquid screening method can screen 96/384 phages per multi-well plate at high throughput, with an automatic real-time bacterial growth monitoring system for scoring based on phage lytic power and bacterial tolerance, completing the lytic phage identification within 4 hours and lytic plus lower-resistant phage identification within 16 hours. The third-generation virtual cPhageBank screening technology uses data mining and deep learning on the CreatiPhage phage-bacteria interaction phenotype database and sequence database, conducting virtual selection of lytic phages based on the key determinant components in the bacteria-phage sequence.

Currently, CreatiPhage offers phage screening service for institutions or individuals, inviting to follow the WeChat public account (创噬纪CreatiPhage) or contact us for more information. Additionally, the CreatiPhage plans to file the diagnosis series for the first approved medical technology (non-restricted category) with the Shanghai Municipal Health Commission through the construction of its own diagnostic laboratory later.

The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are the most common, drug-resistant, and difficult-to-treat pathogens worldwide, causing over 3.2 million related deaths annually, ranking at the top of the WHO's list of 12 superbugs in 2017. In China, 2.168 million cases of ESKAPE infections were monitored in healthcare facilities in 2020. For specific pathogens infected patients, CreatiPhage utilizes its established standard cPhageBank high-throughput phage screening technologies, and phage combination system to quickly select the most suitable personalized phage cocktail formula for treatment. 

Currently, CreatiPhage is working with partner medical institutions to advance the clinical research filing of phage therapy as a New Biomedical Technology. The phage dosage form is a liquid, and the initial indications are Acinetobacter baumannii pneumonia and Klebsiella pneumoniae urinary tract infection, using commonly used clinical administration regimens such as nebulized inhalation and bladder instillation..

For the most common, drug-resistant superbugs that are prone to hospital-acquired infections and transmission within human environments such as healthcare facilities, nursing homes, and households, a series of broad-spectrum phage cocktail products targeting clinically prevalent bacterial strains have been developed. This fixed formula product can be dynamically updated based on changes in clinically prevalent strains with product types including environmental improvement agents in liquid, powder, and tablet forms, suitable for healthcare facilities, nursing homes, and home environments with infected or susceptible individuals. 

The PHAGINK™ series' first pipeline is a fixed formula product targeting targeting clinically prevalent ESKAPE antibiotic-resistant strains, applicable for empirical (non-customized environmental spraying to reduce the risk of transmission of the aforementioned bacteria. Follow our WeChat (CreatiPhage), visit our Taobao/ WeChat store (创噬纪霏集噬菌体商城), or contact us for more information.

In response to non-dominant bacterial strains and other superbugs that cannot be covered by the PHAGINK™ product in human habitation, animal husbandry, and food processing environments, local bacteria are isolated through environmental sampling. On one hand, based on the corresponding phage library's broad-spectrum compatibility, targeted phages are rapidly screened from the cPhageBank and assembled into a full-coverage, semi-customized cocktail. This cocktail is then used for environmental disinfection through the medical and household sprayers designated by CreatiPhage, specifically targeting and eliminating the target bacteria in the environment. Concurrently, for long-term cooperation, bacterial detection and transmission can be monitored by cPhageBank lysis profile of the isolated bacteria (bacterial typing) at different time points and sampling sites, as well as by sequencing the environmental bacterial community, to enable timely intervention, identify weak links in infection control, and make improvements. This customized service is applicable in scenarios such as medical and health institutions, animal welfare and aquaculture organizations, food processing facilities, as well as human habitations.